Literature DB >> 27594777

The Diagnosis and Treatment of Antisynthetase Syndrome.

Leah J Witt1, James J Curran2, Mary E Strek1.   

Abstract

Anti-synthetase syndrome is an autoimmune condition, characterized by antibodies directed against an aminoacycl transfer RNA synthetase along with clinical features that can include interstitial lung disease, myositis, Raynaud's phenomenon, and arthritis. There is a higher prevalence and increased severity of interstitial lung disease in patients with anti-synthetase syndrome, as compared to dermatomyositis and polymyositis, inflammatory myopathies with which it may overlap phenotypically. Diagnosis is made by a multidisciplinary approach, synthesizing rheumatology and pulmonary evaluations, along with serologic, radiographic, and occasionally muscle and/or lung biopsy results. Patients with anti-synthetase syndrome often require multi-modality immunosuppressive therapy in order to control the muscle and/or pulmonary manifestations of their disease. The long-term care of these patients mandates careful attention to the adverse effects and complications of chronic immunosuppressive therapy, as well as disease-related sequelae that can include progressive interstitial lung disease necessitating lung transplantation, pulmonary hypertension, malignancy and decreased survival. It is hoped that greater awareness of the clinical features of this syndrome will allow for earlier diagnosis and appropriate treatment to improve outcomes in patients with anti-synthetase syndrome.

Entities:  

Year:  2016        PMID: 27594777      PMCID: PMC5006392          DOI: 10.1097/CPM.0000000000000171

Source DB:  PubMed          Journal:  Clin Pulm Med


  69 in total

Review 1.  Polymyositis and dermatomyositis (first of two parts).

Authors:  A Bohan; J B Peter
Journal:  N Engl J Med       Date:  1975-02-13       Impact factor: 91.245

2.  Two distinct cytokines released from a human aminoacyl-tRNA synthetase.

Authors:  K Wakasugi; P Schimmel
Journal:  Science       Date:  1999-04-02       Impact factor: 47.728

3.  Detection of antisynthetase syndrome in patients with idiopathic interstitial pneumonias.

Authors:  Kizuku Watanabe; Tomohiro Handa; Kiminobu Tanizawa; Yuji Hosono; Yoshio Taguchi; Satoshi Noma; Yoichiro Kobashi; Takeshi Kubo; Kensaku Aihara; Kazuo Chin; Sonoko Nagai; Tsuneyo Mimori; Michiaki Mishima
Journal:  Respir Med       Date:  2011-04-22       Impact factor: 3.415

4.  Antisynthetase syndrome and malignancy: our experience.

Authors:  Marta Castañeda-Pomeda; Sergio Prieto-González; Josep Maria Grau
Journal:  J Clin Rheumatol       Date:  2011-12       Impact factor: 3.517

Review 5.  Comparison of long-term outcome between anti-Jo1- and anti-PL7/PL12 positive patients with antisynthetase syndrome.

Authors:  I Marie; S Josse; O Decaux; S Dominique; E Diot; C Landron; P Roblot; S Jouneau; P Y Hatron; K P Tiev; O Vittecoq; D Noel; L Mouthon; J-F Menard; F Jouen
Journal:  Autoimmun Rev       Date:  2012-02-03       Impact factor: 9.754

6.  Serum creatine kinase after exercise: drawing the line between physiological response and exertional rhabdomyolysis.

Authors:  Kimbra Kenney; Mark E Landau; Rodney S Gonzalez; Julie Hundertmark; Karen O'Brien; William W Campbell
Journal:  Muscle Nerve       Date:  2012-03       Impact factor: 3.217

7.  Mycophenolate mofetil is safe, well tolerated, and preserves lung function in patients with connective tissue disease-related interstitial lung disease.

Authors:  Jeffrey J Swigris; Amy L Olson; Aryeh Fischer; David A Lynch; Gregory P Cosgrove; Stephen K Frankel; Richard T Meehan; Kevin K Brown
Journal:  Chest       Date:  2006-07       Impact factor: 9.410

8.  Anti-Jo-1 antibody levels correlate with disease activity in idiopathic inflammatory myopathy.

Authors:  Kerry B Stone; Chester V Oddis; Noreen Fertig; Yasuhiro Katsumata; Mary Lucas; Molly Vogt; Robyn Domsic; Dana P Ascherman
Journal:  Arthritis Rheum       Date:  2007-09

9.  Successful conversion from mycophenolate mofetil to enteric-coated mycophenolate sodium (myfortic) in liver transplant patients with gastrointestinal side effects.

Authors:  G Robaeys; D Cassiman; C Verslype; D Monbaliu; R Aerts; J Pirenne; F Nevens
Journal:  Transplant Proc       Date:  2009-03       Impact factor: 1.066

Review 10.  The clinical phenotype associated with myositis-specific and associated autoantibodies: a meta-analysis revisiting the so-called antisynthetase syndrome.

Authors:  Jean-Christophe Lega; Nicole Fabien; Quitterie Reynaud; Isabelle Durieu; Stéphane Durupt; Marine Dutertre; Jean-François Cordier; Vincent Cottin
Journal:  Autoimmun Rev       Date:  2014-04-03       Impact factor: 9.754

View more
  41 in total

1.  [Progressive respiratory failure and weakness in a 61-year-old woman].

Authors:  M Mahmud; U Schnoor; O M Steinmetz
Journal:  Internist (Berl)       Date:  2019-02       Impact factor: 0.743

2.  Characteristics and outcomes of overlap myositis: a comparative multigroup cohort study in adults from the MyoCite cohort.

Authors:  R Naveen; Upendra Rathore; Vikas Agarwal; Latika Gupta
Journal:  Rheumatol Int       Date:  2021-01-10       Impact factor: 2.631

3.  A call for uniformity in implementing the IPAF (interstitial pneumonia with autoimmune features) criteria.

Authors:  Mary E Strek; Justin M Oldham; Ayodeji Adegunsoye; Rekha Vij
Journal:  Eur Respir J       Date:  2016-12       Impact factor: 16.671

Review 4.  Autoantibodies in myositis.

Authors:  Neil J McHugh; Sarah L Tansley
Journal:  Nat Rev Rheumatol       Date:  2018-04-20       Impact factor: 20.543

5.  Lesson of the month 2: Fever, arthralgias and hyperkeratotic, scaling and fissuring eruptions of the hands.

Authors:  Evangelia Zampeli; Haralampos M Moutsopoulos
Journal:  Clin Med (Lond)       Date:  2019-05       Impact factor: 2.659

Review 6.  Evolution of the multi-tRNA synthetase complex and its role in cancer.

Authors:  Do Young Hyeon; Jong Hyun Kim; Tae Jin Ahn; Yeshin Cho; Daehee Hwang; Sunghoon Kim
Journal:  J Biol Chem       Date:  2019-02-19       Impact factor: 5.157

7.  Mycophenolate in idiopathic inflammatory myositis: outcome data of a large South Asian cohort.

Authors:  Aswin M Nair; John Mathew; Ruchika Goel; Pramod Chebbi; Ashish Jacob Mathew; G Arvind; Bijesh Yadav; Grace Rebekah; John A J Prakash; Debashish Danda
Journal:  Clin Rheumatol       Date:  2021-01-27       Impact factor: 2.980

Review 8.  Autoimmune Myopathies: Updates on Evaluation and Treatment.

Authors:  Emer R McGrath; Christopher T Doughty; Anthony A Amato
Journal:  Neurotherapeutics       Date:  2018-10       Impact factor: 7.620

9.  Clinical characteristics of interstitial lung diseases positive to different anti-synthetase antibodies.

Authors:  Minna Jiang; Xin Dong; Yi Zheng
Journal:  Medicine (Baltimore)       Date:  2021-05-14       Impact factor: 1.889

10.  Clinical Puzzles and Decision-Making in Antisynthetase Syndrome.

Authors:  Yelyzaveta Yehudina; Svitlana Trypilka; Anna Isayeva
Journal:  Cureus       Date:  2021-06-25
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.